Rhythm pharmaceuticals announces oral mc4r agonist bivamelagon achieved statistically significant, clinically meaningful bmi reductions in placebo-controlled phase 2 trial in acquired hypothalamic obesity

-- bivamelagon achieved bmi reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- post-hoc analysis showed bmi reductions in bivamelagon trial were consistent with bmi reductions achieved by setmelanotide in past trials in similar patient populations --
BMI Ratings Summary
BMI Quant Ranking